A randomized trial involving various COVID-19 and influenza vaccines found that concomitant administration was safe and immunogenic.
When COVID-19 vaccines were first authorized, administration of other vaccines was generally separated by at least 2 weeks. As experience accumulated, however, concomitant administration of COVID-19 vaccines with other immunizations became the norm. Now, a randomized clinical trial in the U.K. supports this practice.
About 680 participants were recruited for a six-cohort study of two different COVID-19 vaccines (ChAdOx1 [AstraZeneca] or BNT162b2 [Pfizer-BioNTech]) and three different influenza vaccines. Participants received the second dose of each COVID-19 vaccine either concomitantly with one of the influenza vaccines or spaced apart by 3 weeks.
Mild and moderate vaccine reactions were common, but rates were similar in most cohorts and no s…
Reviewing Author
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)